Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug

被引:0
|
作者
Sethuraman V.V. [1 ]
Hickey A.J. [2 ]
机构
[1] Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill
[2] School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill
关键词
Aerosol dispersion; Cohesive energy density; Dry powder inhalers; Surface area; Surface energy;
D O I
10.1208/pt030428
中图分类号
学科分类号
摘要
The purpose of this study was to determine if aerosol delivery of drug loaded microparticles to lungs infected with Mycobacterium tuberculosis may be achieved by predicting dispersion of dry powders through knowledge of particle surface properties. Particle sizes of rifampicin-loaded poly (lactide-co-glycolide) microparticles (R-PLGA), rifampicin alone, and lactose and maltodextrin carrier particles (bulk and 75-125-μ sieved fractions) were determined by electron microscopy for the projected area diameter (Dp) and laser diffraction for the volume diameter (Dv). Surface energies (y) of R-PLGA, rifampicin alone, lactose, and maltodextrin were obtained by inverse phase gas chromatography, surface areas (Sa) by N2 adsorption, and cohesive energy densities by calculation. Particle dispersion was evaluated (Andersen nonviable impactor) for 10% blends of R-PLGA and rifampicin alone with bulk and sieved fractions of the carriers. Dp for R-PLGA and rifampicin alone was 3.02 and 2.83 μm, respectively. Dv was 13 ± 1 and 2 ± 1 μm for R-PLGA and rifampicin alone, respectively, indicating that R-PLGA was more aggregated. This was evident in y of 35 ± 1 and 19 ± 6 mJ/m 2 for RPLGA and rifampicin alone. Dp for lactose and maltodextrin (sieved and bulk) was approximately 40 mm. Bulk maltodextrin (Dv = 119 ± 6 mm) was more aggregated than bulk lactose (Dv = 54 ± 2 mm). This was a result of the higher Sa for maltodextrin (0.54 m2/g) than for lactose (0.21 m2/g). The y of bulk lactose and maltodextrin was 40 ± 4 and 60 ± 6 mJ/m 2 and of sieved lactose and maltodextrin was 39 ± 1 and 50 ± 1 mJ/m2. Impaction studies yielded higher fine particle fractions of R-PLGA from sieved lactose, 13% ± 3%, than from sieved maltodextrin, 7% ± 1%, at 90 L/min. An expression, based on these data, is proposed as a predictor of drug dispersion from carrier particles. Delivery of dry powder formulations can be achieved by characterizing particle surfaces and predicting impact on dispersion.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Dry powder inhalers for optimal drug delivery
    Newman, SP
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (01) : 23 - 33
  • [42] Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
    Rashid, Md Abdur
    Elgied, Amged Awad
    Alhamhoom, Yahya
    Chan, Enoch
    Rintoul, Llew
    Allahham, Ayman
    Islam, Nazrul
    PHARMACEUTICS, 2019, 11 (05):
  • [43] Dry Powder Inhaler Delivery of Tobramycin in In Vitro Models of Tracheostomized Children
    Wee, Wallace B.
    Tavernini, Scott
    Martin, Andrew R.
    Amirav, Israel
    Majaesic, Carina
    Finlay, Warren H.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2017, 30 (01) : 64 - +
  • [44] Systemic Delivery of Atropine Sulfate by the MicroDose Dry-Powder Inhaler
    Corcoran, T. E.
    Venkataramanan, R.
    Hoffman, R. M.
    George, M. P.
    Petrov, A.
    Richards, T.
    Zhang, S.
    Choi, J.
    Gao, Y. Y.
    Oakum, C. D.
    Cook, R. O.
    Donahoe, M.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2013, 26 (01) : 46 - 55
  • [45] Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
    Rashid, Md Abdur
    Muneer, Saiqa
    Wang, Tony
    Alhamhoom, Yahya
    Rintoul, Llew
    Izake, Emad L.
    Islam, Nazrul
    PLOS ONE, 2021, 16 (04):
  • [46] Novolizer®A Multidose Dry Powder Inhaler
    Caroline Fenton
    Gillian M. Keating
    Greg L. Plosker
    Drugs, 2003, 63 : 2437 - 2445
  • [47] Powder Production and Particle Engineering for Dry Powder Inhaler Formulations
    Lin, Yu-Wei
    Wong, Jennifer
    Qu, Li
    Chan, Hak-Kim
    Zhou, Qi
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (27) : 3902 - 3916
  • [48] The Genuair® inhaler: a novel, multidose dry powder inhaler
    Chrystyn, H.
    Niederlaender, C.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2012, 66 (03) : 309 - 317
  • [49] Influence of surface interaction between drug and excipient in binary mixture for dry powder inhaler applications
    Varun, Neetu
    Dutta, Arnab
    Ghoroi, Chinmay
    ADVANCED POWDER TECHNOLOGY, 2022, 33 (03)
  • [50] Developing Dry Powder Inhaler Formulations
    Morton, David A. V.
    Barling, David
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2024, 37 (02) : 90 - 99